Difference in imaging biomarkers of neurodegeneration between early and late-onset amnestic Alzheimer's disease

Neurobiol Aging. 2017 Jun:54:22-30. doi: 10.1016/j.neurobiolaging.2017.02.010. Epub 2017 Feb 21.

Abstract

Neuroimaging biomarkers differ between patients with early-onset Alzheimer's disease (EOAD) and late-onset Alzheimer's disease (LOAD). Whether these changes reflect cognitive heterogeneity or differences in disease severity is still unknown. This study aimed at investigating changes in neuroimaging biomarkers, according to the age of onset of the disease, in mild amnestic Alzheimer's disease patients with positive amyloid biomarkers in cerebrospinal fluid. Both patient groups were impaired on tasks assessing verbal and visual recognition memory. EOAD patients showed greater executive and linguistic deficits, while LOAD patients showed greater semantic memory impairment. In EOAD and LOAD, hypometabolism involved the bilateral temporoparietal junction and the posterior cingulate cortex. In EOAD, atrophy was widespread, including frontotemporoparietal areas, whereas it was limited to temporal regions in LOAD. Atrophic volumes were greater in EOAD than in LOAD. Hypometabolic volumes were similar in the 2 groups. Greater extent of atrophy in EOAD, despite similar extent of hypometabolism, could reflect different underlying pathophysiological processes, different glucose-based compensatory mechanisms or distinct level of premorbid atrophic lesions.

Keywords: Age of onset; Alzheimer's disease; Magnetic resonance imaging; Neuroimaging biomarkers; Positron emission tomography imaging.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Alzheimer Disease / diagnostic imaging*
  • Alzheimer Disease / metabolism
  • Alzheimer Disease / pathology*
  • Amyloid / cerebrospinal fluid
  • Atrophy
  • Biomarkers* / cerebrospinal fluid
  • Brain / diagnostic imaging
  • Brain / metabolism
  • Brain / pathology
  • Cognition
  • Female
  • Glucose / metabolism
  • Humans
  • Magnetic Resonance Imaging*
  • Male
  • Memory
  • Middle Aged
  • Nerve Degeneration
  • Neuroimaging*
  • Positron-Emission Tomography*
  • Severity of Illness Index

Substances

  • Amyloid
  • Biomarkers
  • Glucose